GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million

Reuters03-25

GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million

GenFleet published an annual results announcement for the year ended Dec. 31, 2025.
Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with Verastem.
Loss for the year was RMB1.8 billion, while adjusted loss (non-IFRS) narrowed 9.3% to RMB226.5 million.
Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.
Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065860), on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622011788?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 07:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622011788","market":"fut","top_or_hot":-1,"title":"GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          GenFleet published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>.\n        </li>\n<li>\n          Loss for the year was RMB1.8 billion, while adjusted loss (non-IFRS) narrowed 9.3% to RMB226.5 million.\n        </li>\n<li>\n          Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.\n        </li>\n<li>\n          Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065860), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 07:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          GenFleet published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>.\n        </li>\n<li>\n          Loss for the year was RMB1.8 billion, while adjusted loss (non-IFRS) narrowed 9.3% to RMB226.5 million.\n        </li>\n<li>\n          Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.\n        </li>\n<li>\n          Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065860), on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8wv7nJ:1","article_id":"2622011788","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622011788","pubTimestamp":1774395095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"GenFleet published an annual results announcement for the year ended Dec. 31, 2025.Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with Verastem.Loss for the year was RMB1.8 billion, while adjusted loss  narrowed 9.3% to RMB226.5 million.Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics  Inc. published ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK1161":"生物科技","02595":"劲方医药-B","VSTM":"Verastem"},"translate_title":"Genfleet 2025财年净亏损扩大至17.9亿元，营收增长24.41%至1.3亿元","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":0.9,"VSTM":0.9},"content_text":"GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million\n    \n\n\n          GenFleet published an annual results announcement for the year ended Dec. 31, 2025.\n        \n\n          Revenue rose 24.42% to RMB130.3 million, driven primarily by the GFH375 collaboration and out-licensing arrangement with Verastem.\n        \n\n          Loss for the year was RMB1.8 billion, while adjusted loss (non-IFRS) narrowed 9.3% to RMB226.5 million.\n        \n\n          Research and development costs fell 15.01% to RMB282.3 million, mainly due to lower termination and patent licensing fees recorded in 2024.\n        \n\n          Cash and bank balances were RMB2.1 billion as of Dec. 31, 2025, and management said it expects to generate more operating cash flow through commercialization of fulzerasib and additional third-party collaborations.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfleet Therapeutics (Shanghai) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260325-12065860), on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622011788","isCrawlerRequest":true}